Document is current

Article History

Received: 18 June 2018

Accepted: 21 September 2018

First Online: 11 October 2018

Ethics approval and consent to participate

: Not applicable.

: Clinical, imaging and laboratory data obtained under an IRB-approved protocol at Johns Hopkins, IRB00144013.

: Conflicts of interest / disclosures are as follows:Kendall F. Moseley: Author has no conflicts of interestClifton O. Bingham: Consultant and research support from Bristol-Myers SquibbMichael A. Carducci: Consultant for Pfizer, Merck, Astellas, Roche-Genentech; research support from Bristol-Myers Squibb, Pfizer, ExelexisPatrick Forde: Consultant for AstraZeneca, Abbvie, Bristol-Myers Squibb, EMD Serono, Merck, Novartis; research support AstraZeneca, Bristol-Myers Squibb, Kyowa, NovartisGeoffrey T. Gibney: Consultant for Novartis, Genentech, Newlink Genetics, and Incyte; speaker for Merck, GenentechEvan J. Lipson: Consultant for Array Biopharma, Bristol-Myers Squibb; research support from Bristol-Myers Squibb, MerckJarushka Naidoo: Consultant for Bristol-Myers Squibb, AstraZeneca, Takeda; research support from Bristol-Myers Squibb, MerckAmi A. Shah: Consultant for Bristol-Myers SquibbWilliam H. Sharfman: Consultant for Merck, Bristol-Meyers Squibb and Novartis; Research support from Merck, Bristol-Meyers Squibb and NovartisLaura C. Cappelli: Research support from Bristol-Meyers Squibb

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.